ICU SeaStar Medical Holding Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1831868 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY145.7%
TTM net income YoY-7.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin92.6%
Operating margin-692.4%
Net margin-678.2%
FCF margin—
EBITDA margin—
Returns
ROE-246.1%
ROA-140.9%
ROIC (approx.)—
Asset turnover0.21x
Leverage & solvency
Liabilities / assets91.2%
Debt / equity0.00x
Current ratio1.03x
Interest coverage-516.93x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $635,000 | $615,000 | $495,000 | $420,000 | $183,000 | $338,000 | $293,000 | $67,000 |
| Cost of revenue | $48,000 | $54,000 | $46,000 | $12,000 | $14,000 | $27,000 | $0 | $0 |
| Gross profit | $587,000 | $561,000 | $449,000 | $408,000 | $169,000 | $311,000 | $293,000 | $67,000 |
| R&D expense | $3.57M | $2.52M | $2.34M | $2.20M | $1.85M | $1.04M | $2.43M | $2.74M |
| SG&A expense | $1.59M | $1.83M | $1.71M | $1.22M | $1.90M | $1.03M | $1.68M | $2.10M |
| Operating income | -$4.58M | -$3.79M | -$3.60M | -$3.02M | -$3.58M | -$1.76M | -$3.82M | -$4.77M |
| Interest expense | $2,000 | $8,000 | $6,000 | $13,000 | $0 | $9,000 | $11,000 | -$253,000 |
| Pretax income | -$4.53M | -$3.73M | -$3.52M | -$2.90M | -$3.47M | -$2.00M | -$3.77M | -$4.42M |
| Income tax | $0 | $0 | $3,000 | $0 | $0 | $0 | $3,000 | $0 |
| Net income | -$4.53M | -$3.73M | -$3.52M | -$2.90M | -$3.47M | -$2.00M | -$3.77M | -$4.42M |
| EPS (basic) | -1.03 | -0.91 | -0.90 | — | -1.30 | -1.77 | -4.38 | — |
| EPS (diluted) | — | — | — | — | — | -0.18 | -0.44 | — |
| Weighted avg. shares (diluted) | — | — | — | — | — | 11.33M | 8.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.99M | $6.96M | $9.35M | $11.98M | $13.76M | $6.30M | $5.30M | $1.82M |
| Receivables | $178,000 | $208,000 | $179,000 | $237,000 | $221,000 | $217,000 | $110,000 | $112,000 |
| Inventory | $45,000 | $77,000 | $57,000 | $66,000 | $83,000 | $77,000 | $44,000 | $0 |
| Current assets | $4.97M | $8.23M | $10.76M | $13.58M | $14.87M | $7.65M | $6.78M | $3.77M |
| Total assets | $5.31M | $8.65M | $11.26M | $14.16M | $15.53M | $8.38M | $14.20M | $4.66M |
| Current liabilities | $4.84M | $4.35M | $3.95M | $3.74M | $4.07M | $5.04M | $7.03M | $6.84M |
| Short-term debt | — | — | — | — | — | — | — | $574,000 |
| Total liabilities | $4.84M | $4.35M | $3.95M | $3.74M | $4.07M | $5.04M | $7.03M | $6.84M |
| Shareholders' equity | $469,000 | $4.30M | $7.32M | $10.42M | $11.46M | $3.34M | $565,000 | -$2.18M |
| Shares outstanding | 4.46M | 4.26M | 3.99M | 3.84M | 34.10M | 17.34M | 9.26M | 650,639 |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.37M | -$2.99M | -$2.76M | -$4.09M | -$3.84M | -$3.01M | -$2.65M | -$4.69M |
| Financing cash flow | $403,000 | $605,000 | $129,000 | $2.31M | $11.30M | $4.01M | $6.13M | $4.43M |
| Stock-based compensation | $163,000 | -$99,000 | $91,000 | $70,000 | $290,000 | $97,000 | $167,000 | $212,000 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.